Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPK Pathway Inhibition Combined With Anti-PD1 for BRAF-altered Pediatric Gliomas
NCT06712875Phase 2Recruiting
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in glioma, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06712875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06712875.